HRAS and cancer: Most evaluate cancer risk by testing for known driver mutations—including BRAF, NRAS, HRAS, EIF1AX and KRAS. Additionally, some complement with their own genomic panel, evaluating other features such as gene fusions, copy-number alterations, and/or gene expression alterations.